Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$11.41M
EBITDA Margin
-19.85%
TTM Avg
-31.46%
3Y Avg
-46.77%
5Y Avg
-56.23%
Market Cap
$11.01M
EBITDA Margin
-5650.91%
TTM Avg
-5650.91%
3Y Avg
-12817.85%
5Y Avg
-12817.85%
Market Cap
$11.95M
EBITDA Margin
-1346.05%
TTM Avg
-2835.20%
3Y Avg
-1619.25%
5Y Avg
-1619.25%
Market Cap
$10.74M
EBITDA Margin
-284.92%
TTM Avg
-261.31%
3Y Avg
-2315.78%
5Y Avg
-2461.07%
Market Cap
$12.46M
EBITDA Margin
-34.02%
TTM Avg
-37.67%
3Y Avg
-64.98%
5Y Avg
-56.41%
Market Cap
$10.27M
EBITDA Margin
-133689.80%
TTM Avg
-133689.80%
3Y Avg
-133689.80%
5Y Avg
-133689.80%
Market Cap
$12.63M
EBITDA Margin
-1106.68%
TTM Avg
-120183.14%
3Y Avg
-60445.11%
5Y Avg
-60445.11%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adial Pharmaceuticals, Inc. (ADIL) | $11.42M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.41M | -19.85% | -31.46% | -46.77% | -56.23% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.01M | -5650.91% | -5650.91% | -12817.85% | -12817.85% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.95M | -1346.05% | -2835.20% | -1619.25% | -1619.25% |
| BioVie Inc. (BIVI)vs › | $10.86M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.74M | -284.92% | -261.31% | -2315.78% | -2461.07% |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | -34.02% | -37.67% | -64.98% | -56.41% |
| Caring Brands, Inc. (CABR)vs › | $10.27M | -133689.80% | -133689.80% | -133689.80% | -133689.80% |
| Dare Bioscience, Inc. (DARE)vs › | $12.63M | -1106.68% | -120183.14% | -60445.11% | -60445.11% |
| Ainos, Inc. (AIMD)vs › | $9.79M | -7418.23% | -25513.08% | -14528.12% | -11171.17% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
